We are not talking about vaccine efficiency or efficacy here though but adverse events specifically.
>If we check the data for say the Pfizer trial, what we see is no effect on mortality
The point is that there are almost no serious adverse events occuring post-vaccination. There is no pharmacovigilance safety signal or concerning pattern wrt MRNA-vaccines. As we have seen in 2021 with the astra zeneca vaccine, post market surveillance worked and it was promptly investigated as soon as a safety signal emerged. EMA (and other regulatory agencies) communicated transparently about their findings and decisions.
Thank you for reminding me of this fine example of post-market surveillance, I almost forgot :)
>If we check the data for say the Pfizer trial, what we see is no effect on mortality
The point is that there are almost no serious adverse events occuring post-vaccination. There is no pharmacovigilance safety signal or concerning pattern wrt MRNA-vaccines. As we have seen in 2021 with the astra zeneca vaccine, post market surveillance worked and it was promptly investigated as soon as a safety signal emerged. EMA (and other regulatory agencies) communicated transparently about their findings and decisions.
Thank you for reminding me of this fine example of post-market surveillance, I almost forgot :)